6th World Parkinson Congress
NLX-112 has Favorable Safety, Tolerability and Efficacy Against Levodopa-Induced Dyskinesia (LID) in a Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Ph2A Study
By
6th World Parkinson Congress
FEATURING
Adrian Newman-Tancredi
By
6th World Parkinson Congress
FEATURING
Adrian Newman-Tancredi
Comments 0
Login to view comments.
Click here to Login
